US Grand Mal Seizure Market

ID: MRFR/Pharma/17828-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026
US Grand Mal Seizure Market Research Report By Drug Class (hydantoin, barbiturates, benzodiazepines, phenyltriazine, cyclic GABA analogs, aliphatic carboxylic acid, iminostilbenes, others), By Diagnosis (magnetic resonance imaging (MRI), electroencephalogram (EEG), blood tests, computed tomography (CT), others), By Drug Generation (the third generation, the second generation, the first generation), By Surgery (multiple subpial transections, resective surgery, corpus callosotomy, hemispherectomy, others) and By End Users (academic and research centers, neurological centers, hospitals, others) - Growth & Industry Forecast 2025 To 2035
US Grand Mal Seizure Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.88%
2024 Market Size$ 0.6 Million
2025 Market Size$ 0.64 Million
2035 Market Size$ 1.25 Million
Key Players
Pfizer Inc
Novartis AG
Eli Lilly and Company
Sanofi S.A.
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd
Trends
  • Advancements in Treatment Options
  • Increased Awareness and Education
  • Integration of Telemedicine
Opportunities
  • Innovative Drug Development
  • Rising Incidence of Epilepsy
  • Increased Healthcare Expenditure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY drug class (USD Million)
      1. 4.1.1 hydantoin
      2. 4.1.2 barbiturates
      3. 4.1.3 benzodiazepines
      4. 4.1.4 phenyltriazine
      5. 4.1.5 cyclic GABA analogs
      6. 4.1.6 aliphatic carboxylic acid
      7. 4.1.7 iminostilbenes
      8. 4.1.8 others
    2. 4.2 Healthcare, BY diagnosis (USD Million)
      1. 4.2.1 magnetic resonance imaging (MRI)
      2. 4.2.2 electroencephalogram (EEG)
      3. 4.2.3 blood tests
      4. 4.2.4 computed tomography (CT)
      5. 4.2.5 others
    3. 4.3 Healthcare, BY drug generation (USD Million)
      1. 4.3.1 the third generation
      2. 4.3.2 the second generation
      3. 4.3.3 the first generation
    4. 4.4 Healthcare, BY surgery (USD Million)
      1. 4.4.1 multiple subpial transections
      2. 4.4.2 resective surgery
      3. 4.4.3 corpus callosotomy
      4. 4.4.4 hemispherectomy
      5. 4.4.5 others
    5. 4.5 Healthcare, BY end-users (USD Million)
      1. 4.5.1 academic and research centers
      2. 4.5.2 neurological centers
      3. 4.5.3 hospitals
      4. 4.5.4 others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis AG (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eli Lilly and Company (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi S.A. (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bristol-Myers Squibb Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca PLC (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Johnson & Johnson (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 US MARKET ANALYSIS BY DRUG GENERATION
    5. 6.5 US MARKET ANALYSIS BY SURGERY
    6. 6.6 US MARKET ANALYSIS BY END-USERS
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY DRUG GENERATION, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY DRUG GENERATION, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY SURGERY, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY SURGERY, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY END-USERS, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY END-USERS, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY DRUG GENERATION, 2025-2035 (USD Million)
      4. 7.2.4 BY SURGERY, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Grand Mal Seizure Market Segmentation

US Grand Mal Seizure Market By drug class (USD Million, 2025-2035)

  • hydantoin
  • barbiturates
  • benzodiazepines
  • phenyltriazine
  • cyclic GABA analogs
  • aliphatic carboxylic acid
  • iminostilbenes
  • others

US Grand Mal Seizure Market By diagnosis (USD Million, 2025-2035)

  • magnetic resonance imaging (MRI)
  • electroencephalogram (EEG)
  • blood tests
  • computed tomography (CT)
  • others

US Grand Mal Seizure Market By drug generation (USD Million, 2025-2035)

  • the third generation
  • the second generation
  • the first generation

US Grand Mal Seizure Market By surgery (USD Million, 2025-2035)

  • multiple subpial transections
  • resective surgery
  • corpus callosotomy
  • hemispherectomy
  • others

US Grand Mal Seizure Market By end-users (USD Million, 2025-2035)

  • academic and research centers
  • neurological centers
  • hospitals
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.